<h4>Objective</h4>To characterize the clinical trial landscape of PI3K inhibitors in breast cancer and evaluate their efficacy, safety, and publication status.<h4>Methods</h4>We searched eight major clinical trial databases using standardized MeSH/Emtree terms up to January 1, 2026. This evidence concerns the gene PIK3CA and breast cancer.